Company: DNLI
Filing Date: 2025-08-11
Form Type: 10-Q
Source: 0001714899-25-000170
Chunk: 182

Company: Denali Therapeutics Inc.
Filing Date: 2025-08-11
Form: 10-Q
Item: Part I, Item 1
Chunk 182
---
ITEM 1.    FINANCIAL STATEMENTS

Denali Therapeutics Inc.

Condensed Consolidated Balance Sheets

(Unaudited)

(In thousands, except share amounts)

June 30, 2025December 31, 2024AssetsCurrent assets:Cash and cash equivalents$141,207 $174,960 Short-term marketable securities757,745 657,371 Prepaid expenses and other current assets35,754 32,105 Total current assets934,706 864,436 Long-term marketable securities78,463 359,373 Property and equipment, net58,717 55,236 Finance lease right-of-use asset50,363 47,533 Operating lease right-of-use asset21,022 22,861 Other non-current assets22,970 24,741 Total assets$1,166,241 $1,374,180 Liabilities and stockholders' equity Current liabilities:Accounts payable$10,844 $11,137 Accrued compensation12,068 24,728 Accrued clinical and other research and development costs23,379 22,822 Accrued manufacturing costs9,028 12,779 Operating lease liability, current8,871 8,308 Deferred research and development funding liability, current19,861 14,129 Other accrued costs and current liabilities7,006 8,305 Total current liabilities91,057 102,208 Operating lease liability, less current portion32,110 36,673 Finance lease liability, less current portion5,577 5,615 Deferred research funding and development liability, less current portion10,444 — Total liabilities139,188 144,496 Commitments and contingencies (Note 6)Stockholders' equity:Convertible preferred stock, $0.01 par value; 40,000,000 shares authorized as of June 30, 2025 and December 31, 2024; 0 shares issued and outstanding as of June 30, 2025 and December 31, 2024— — Common stock, $0.01 par value; 400,000,000 shares authorized as of June 30, 2025 and December 31, 2024; 145,685,442 shares and 144,220,986 shares issued and outstanding as of June 30, 2025 and December 31,